Form 4: HealthEquity Director Neeleman Executes Stock Option and Sells Shares Under 10b5-1 Plan

Stephen Neeleman, a Director and Officer of HealthEquity, Inc., exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On June 4, 2024, Stephen Neeleman, a Director and Officer (Founder and Vice Chairman) of HealthEquity, Inc. (HQY), executed transactions involving the company's common stock.
• Neeleman exercised a stock option to acquire 400 shares at a price of $14.
• Simultaneously, Neeleman sold 400 shares at $85.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2023.
• Following these transactions, Neeleman directly owns 90,515 shares of common stock and holds options to purchase additional shares.
• Neeleman also indirectly owns 559,235 shares through the Stephen and Christine Neeleman Trust and 203,000 shares through Neeleman Family Holdings, LLC.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions under a pre-arranged trading plan. There's no indication of unusual or concerning activity.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can provide transparency and reduce concerns about insider trading.

Risks

• While the transactions are under a 10b5-1 plan, significant insider selling could potentially create negative market sentiment.

Industry Context

Insider transactions are common and closely monitored in the healthcare technology sector. Form 4 filings provide transparency into the trading activities of company insiders.

Comparison to Industry Standards

• Monitoring insider trading activity is a standard practice across publicly traded companies, especially in sectors like healthcare technology where regulatory scrutiny is high.
• Companies like Teladoc Health and Accolade also have insiders who regularly file Form 4s, reflecting stock option exercises and sales.

Stakeholder Impact

• The transactions could have a minor impact on shareholders, depending on their interpretation of insider selling activity.

Key Dates